BEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales.

The Division is expected to use blockchain technology to build an efficient ecosystem for managing and leveraging biological cell assets. Its primary goals are (1) to promote the standardized management of biological cell assets; to establish an induced pluripotent stem cells ("IPSC") cell bank; to achieve blockchain-linking; to establish compliance frameworks so that biological cell assets can be clearly traced and securely confirmed; and (2) to develop supporting industry blockchain tools such as equity transfer mechanisms to address the problem of the low efficiency of cell asset circulation.

The work to be undertaken by the Division is anticipated to allow medical and research institutions to allocate resources more flexibly, and it is contemplated to lower the threshold for users to obtain services through flexible payments and other methods. In addition, the Company believes it will streamline the connection between service interfaces and storage appointments, create cross-institutional research collaborations, enhance health data management and introduce artificial intelligence ("AI") tools to optimize the service experience. A key goal of this new business initiative is to make cell technology services more accessible to global users.

Mr. Lin Hongguang, formerly Chief Researcher at the Korea Digital Currency Research Institute, has extensive experience in the blockchain and digital asset industries, providing strategic, economic modeling, and listing advisory services to numerous Web3 projects. Mr. Lin specializes in digital asset compliance, token design and international implementation, and has extensive international market resources. As General Manager, Mr. Lin will oversee the Division's strategic planning, daily operations, and team building. In addition, Mr. Lin's responsibilities include developing standards for on-chain cell asset listings, expanding global ecosystem collaborations, promoting the implementation of service scenarios, facilitating compliance filings, and ultimately contributing to the establishment of a global distribution network for biological cell products.

"Bio-cell technology is a core driving force of the 'big health' industry, but the industry currently faces challenges such as low global circulation efficiency, difficulty in cross-regional collaboration, and high user service thresholds," said Jennifer Zhan, CEO of Shineco. "We established the Biological Cell Digital Division precisely to break through these bottlenecks through a cell asset chain model. We believe this will not only enable people to more easily access cell technology services but also promote a significant increase in the global market share of Shineco's biological cell products as well as create long-term value for our shareholders. We view this endeavor as a core element of our corporate growth plan, and it represents a strategic investment in the future of the industry."

About Shineco, Inc.

Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.

For more information, please contact:

Shineco, Inc.

secretary@shineco.tech

Mobile: +86-010-68130220

View original content:https://www.prnewswire.com/news-releases/shineco-establishes-biological-cell-digital-division-to-integrate-biological-cell-assets-and-blockchain-technology-302528817.html

SOURCE Shineco,Inc.

Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology